肠-相互作用加强了在糖尿病病中通过达帕格利弗洛辛的缓解作用
Yinhua Ni1, Haimei Du1, Lehui Ke1
1College of Biotechnology and Bioengineering, Zhejiang University of Technology, Hangzhou, China.
American journal of physiology. Cell physiology
|December 31, 2024
概括
达帕格利弗洛辛通过改变肠道微生物群和代谢物而改善糖尿病病 (DN),而不仅仅是血糖. 这种肠轴的重塑为DN管理提供了一个新的治疗策略.
科学领域:
- 微生物学 微生物学
- 腎臟病學 (nephrology) 是一種醫學.
- 药理学 药理学是指药理学的学科.
背景情况:
- 糖尿病病 (DN) 涉及肠道微生物群失生症.
- 达帕格利弗洛辛在DN中表现出有效性,但除了血糖控制之外的机制尚不清楚.
- 肠轴是达帕格利弗洛辛对DNA影响的潜在媒介.
研究的目的:
- 调查达帕格利弗洛辛对DNA和肠道微生物群的影响.
- 为了阐明达帕格利弗洛辛如何通过肠轴减轻DN.
- 为了确定与达帕格利弗洛辛治疗相关的特定微生物和代谢变化.
主要方法:
- 使用高脂肪饮食/链毒素诱导的DN小鼠和db/db小鼠模型.
- 服用低剂量的达帕格利弗洛辛,评估功能,炎症,纤维化和肠道屏障.
- 在体内和体外 (HK-2细胞) 分析了肠道微生物的组成,功能和关键代谢物 (ASA,PA,SAC).
主要成果:
- 低剂量达帕格利弗洛辛改善了炎/纤维化,改善了肠道屏障功能,但没有改变血糖.
- 微生物群的根除取消了达帕格利弗洛辛的保护作用,证实了它对肠道微生物群的依赖.
- 达帕格利弗洛辛改变了微生物代谢物,降低了ASA/PA,增加了SAC;特定的属 (Muribaculaceae,Desulfovibrionaceae) 与脏保护相关.
结论:
- 达帕格利弗洛辛通过调节肠道微生物群及其代谢产物,对DN产生脏保护作用.
- 肠-轴在达帕格利弗洛辛对DN的治疗作用中起着至关重要的作用.
- 用达帕格利弗洛辛准肠道微生物群是治疗糖尿病病的一个有希望的策略.
相关概念视频
01:23Dipeptidyl Peptidase 4 Inhibitors
166
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
166
01:22Heart Failure Drugs: Diuretics
338
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
338
01:16Antihypertensive Drugs: Action of Diuretics
617
Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
617
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
445
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
445
01:11Renal Failure: Dose Adjustments
62
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
62
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
381
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
381